24/7 Market News Snapshot 24 June, 2025 – TNF Pharmaceuticals, Inc. Common Stock (NASDAQ:TNFA)

June 24, 2025

DENVER, Colo., 24 June, 2025 (www.247marketnews.com) – (Nasdaq:TNFA) are discussed in this article.
TNF Pharmaceuticals, Inc. (Nasdaq:TNFA), a clinical-stage biopharmaceutical firm dedicated to developing therapies for autoimmune and inflammatory diseases, has emerged as a focal point in the market, opening at $0.134 and currently trading at $0.143, reflecting an increase of approximately 3.62%. The trading volume has reached 7.55 million shares, indicating a robust level of investor interest that suggests potential upward momentum. This performance could pave the way for further gains should the stock surpass key resistance levels. However, it will be crucial to monitor the relative strength index (RSI) to prevent overbought conditions.

In a strategic move, TNF Pharmaceuticals has entered a significant partnership with the DADA2 Foundation to advance research on DADA2 (Deficiency of Adenosine Deaminase 2), a rare autoinflammatory condition characterized by complications including systemic inflammation, early-onset stroke, and immune system challenges. The collaboration aims to launch a Compassionate Use study to evaluate TNF’s leading candidate, isomyosamine, for addressing the needs of affected patients, particularly children.

Dr. Mitchell Glass, President and Chief Medical Officer of TNF, articulated the potential of TNF inhibition as a critical intervention for managing the disease’s inflammatory effects, citing isomyosamine’s promising attributes as an orally administered small molecule with a favorable safety profile. Dr. Chip Chambers, Founder and President of the DADA2 Foundation, underscored the necessity for new treatments, given the limitations of current biological TNF inhibitors.

Currently, the DADA2 community consists of over 600 diagnosed patients, with an estimated additional 35,000 individuals potentially impacted but undiagnosed globally. This partnership is poised to make significant strides in addressing the unmet medical needs of the DADA2 population, marking a pivotal step forward in the realm of rare disease treatment and patient care.

Related news for (TNFA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.